724469-18-5

Upstream product

• 724469-17-4 (5-{3-[(2-chloro-5-methyl-pyrimidin-4-yl)-methyl-amino]-propoxy}-indan-1-yl)-acetic acid ethyl ester 
• 63139-21-9 4-ethylphenylboronic acid 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 5111-70-6 5-methoxy-1-indanone 
• 162713-88-4 ethyl (5-methoxy-2,3-dihydro-1H-inden-1-yl)ethanoate 
• 73809-30-0 ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate 
• 724469-81-2 {5-[3-(2-chloro-5-methyl-pyrimidin-4-ylamino)-propoxy]-indan-1-yl}-acetic acid ethyl ester 
• 496061-80-4 ethyl [(1S)-5-hydroxy-2,3-dihydro-1H-inden-1-yl]acetate 
• 496061-79-1 ethyl [(1S)-5-methoxy-2,3-dihydro-1H-inden-1-yl]acetate 
• 496061-78-0 [(1S)-5-methoxy-2,3-dihydro-1H-inden-1-yl]acetic acid 
• 724469-14-1 3-(2-chloro-5-methyl-pyrimidin-4-ylamino)-propan-1-ol 

Relevant academic research and scientific papers

Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups-new classes of PPAR γ/δ and PPAR α/γ/δ agonists

Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications. The indanylacetic acid structural motif has proven useful in the generation of potent and tunable PPAR ligands. Mod